세계의 뇌척수염 시장 보고서(2025년)

Encephalomyelitis Global Market Report 2025

US $ 4,490 ￦ 6,183,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 8,938,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,692,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

뇌척수염 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 예측 기간의 성장은 면역 요법 치료의 채용 증가, 자가 면역 질환의 유병률 증가, 건강 관리 지출 증가, 임상 연구의 확대, 뇌척수염에 대한 인식과 교육 증가에 기인하고 있습니다. 질병 연구에 대한 정부와 민간 자금 제공 증가도 중요한 역할을 한다고 생각됩니다. 예측 기간에 있어서의 주요 동향으로서는 선진적인 면역 조절 요법의 개발, 정밀 생물 제제의 진보, 조기 진단을 위한 신규 바이오마커, 맞춤형 치료의 진전, 차세대 항바이러스제의 창출, 임상 연구에 있어서의 AI의 통합 등이 있습니다.

자가면역 질환의 유병률 증가는 향후 몇 년간의 뇌척수염 시장의 성장을 견인할 것으로 예측됩니다. 감염증,식이 요법이나 화학제품에의 노출을 포함한 라이프 스타일의 변화 등의 요인에 의한 곳이 큽니다. 이것은 궁극적으로 환자의 QOL(생활의 질)과 기능적 행복을 향상시킵니다. 예를 들어 2024년 11월 독일에 본사를 둔 기관인 Versorgungsatlas.de는 2022년에 7,324만 1,305명의 보험 가입자 중 630만 4,340명이 최소 한 가지 이상의 자가 면역 질환을 진단받아 8.61%의 원시 유병률을 기록했다고 보고했습니다.

뇌척수염 시장에서 사업을 전개하는 기업은 치료 효과를 높이고 뇌척수염을 관리하기 위한 표적 요법을 개발하기 위해 첨단 단일클론항체 요법의 개발에 주력하고 있습니다. 단클론 항체는 질병에 대한 면역 반응을 돕기 위해 특정 항원에 결합하는 인공적으로 만들어진 단백질입니다. 예를 들어 2023년 3월 일본 제약회사인 중외제약주식회사는 '단일클론항체'를 개발했습니다. 일본 제약회사인 중외제약 주식회사는 인간화 항IL-6 수용체 단일클론항체 Enspryng이 미엘린 올리고교세포 당단백질 항체 관련 질환(MOGAD)과 자가면역성 뇌염(AIE)의 치료로서 후생노동성으로부터 선구 지정을 받았다고 발표했습니다. 이 지정은 혁신적인 치료로서의 엔스플라이그의 가능성을 인정하고, 이러한 신경질환 환자의 암멧 의료 요구에 대응하기 위한 개발 및 승인 심사를 가속화하게 됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 뇌척수염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 뇌척수염 시장 : 성장률 분석
• 세계의 뇌척수염 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 뇌척수염 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 뇌척수염 전체 시장(TAM)

제6장 시장 세분화

• 세계의 뇌척수염 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 말 뇌척수염
• 연관성 뇌척수염
• 항 마이엘린 올리고교세포 당단백질 항체(항MOG)
• 파종성 뇌척수염
• 급성 파종성 뇌척수염
• 에이즈 관련 뇌척수염
• 기타
• 세계의 뇌척수염 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 수술
• 혈장 분리
• 약물 치료
• 기타
• 세계의 뇌척수염 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 클리닉
• 병원
• 기타
• 세계의 뇌척수염 시장 : 말 뇌척수염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 동부 말 뇌척수염
• 서부 말 뇌척수염
• 베네수엘라 말 뇌척수염
• 세계의 뇌척수염 시장 : 연관성 뇌척수염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 급성 파종성 뇌척수염
• 부신 생물성 뇌척수염
• 감염성 뇌척수염
• 세계의 뇌척수염 시장 : 항 마이엘린 올리고교세포 당단백질 항체 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 단상성 미엘린 올리고교세포 당단백질 항체 뇌척수염
• 재발성 미엘린 올리고교세포 당단백질 항체 뇌척수염
• 세계의 뇌척수염 시장 : 뇌척수염 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 바이러스성 뇌척수염
• 세균성 뇌척수염
• 자가면역성 뇌척수염

제7장 지역별/국가별 분석

• 세계의 뇌척수염 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 뇌척수염 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 뇌척수염 시장 : 경쟁 구도
• 뇌척수염 시장 : 기업 프로파일
  • Merck & Co. Inc.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • HiFiBiO Therapeutics
  • Zoetis Services LLC

제31장 기타 주요 기업 및 혁신 기업

• Chugai Pharmaceutical Co. Ltd.
• IDEXX
• Abcam Limited.
• EUROIMMUN Medizinische Labordiagnostika AG
• Eurogentec SA
• Boehringer Ingelheim International GmbH
• Creative Diagnostics
• Atlas Antibodies
• AnaSpec
• VMRD Inc.
• Antibodies Incorporated
• Fresenius Kabi
• Hemispherx Biopharma Inc.
• BioStoneah
• YouSeq Ltd.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

• 뇌척수염 시장(2029년) : 새로운 기회를 제공하는 국가
• 뇌척수염 시장(2029년) : 새로운 기회를 제공하는 부문
• 뇌척수염 시장(2029년) : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Encephalomyelitis refers to the inflammation of both the brain and spinal cord, typically caused by infections, immune system dysfunction, or other underlying medical conditions. This condition can lead to neurological problems, such as muscle weakness, paralysis, and cognitive disturbances.

The main types of encephalomyelitis include equine encephalomyelitis, associated encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody (anti-MOG) encephalomyelitis, encephalomyelitis disseminata, acute disseminated encephalomyelitis, AIDS-related encephalomyelitis, and others. Equine encephalomyelitis is a viral disease affecting horses, caused by the eastern, western, or Venezuelan equine encephalitis viruses, leading to inflammation in the brain and spinal cord. Treatment options for encephalomyelitis include surgery, plasmapheresis, drug treatments, and other methods, and are utilized in various healthcare settings, including clinics and hospitals.

The encephalomyelitis market research report is one of a series of new reports from The Business Research Company that provides encephalomyelitis market statistics, including the encephalomyelitis industry's global market size, regional shares, competitors with a encephalomyelitis market share, detailed encephalomyelitis market segments, market trends and opportunities, and any further data you may need to thrive in the encephalomyelitis industry. This encephalomyelitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The encephalomyelitis market size has grown strongly in recent years. It will grow from $21.16 billion in 2024 to $22.65 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to the increasing prevalence of autoimmune and infectious diseases, a rise in awareness regarding neurological disorders, greater investment in research and development, advancements in healthcare infrastructure, and the expanding applications of immunotherapy.

The encephalomyelitis market size is expected to see strong growth in the next few years. It will grow to $29.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to the increasing adoption of immunotherapy treatments, a rising prevalence of autoimmune disorders, growing healthcare expenditure, expanded clinical research, and greater awareness and education about encephalomyelitis. Additionally, the rising government and private funding for rare disease research will play a key role. Major trends in the forecast period include the development of advanced immunomodulatory therapies, advancements in precision biologics, novel biomarkers for early diagnosis, progress in personalized treatments, the creation of next-generation antivirals, the integration of AI in clinical research, and innovative gene therapy approaches.

The growing prevalence of autoimmune diseases is expected to drive the growth of the encephalomyelitis market in the coming years. Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own healthy cells and tissues. The rise in autoimmune diseases is largely attributed to factors such as genetic predisposition, environmental triggers, infections, and lifestyle changes, including diet and exposure to chemicals. Encephalomyelitis treatment helps autoimmune disease patients by reducing inflammation, managing immune system dysfunction, alleviating neurological symptoms, and preventing disease progression. This ultimately enhances their quality of life and functional well-being. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Therefore, the rising incidence of autoimmune diseases is driving the growth of the encephalomyelitis market.

Companies operating in the encephalomyelitis market are focusing on the development of advanced monoclonal antibody therapies to enhance treatment efficacy and create targeted therapies for managing encephalomyelitis. Monoclonal antibodies are artificially created proteins that bind to specific antigens to assist the immune response against diseases. For instance, in March 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, announced that its humanized anti-IL-6 receptor monoclonal antibody, Enspryng, received forerunner designation from the Ministry of Health, Labor and Welfare (MHLW) for its anticipated use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). This designation recognizes Enspryng's potential as an innovative treatment, accelerating its development and regulatory review to address the unmet medical needs of patients with these neurological conditions.

In January 2024, Zuellig Pharma Holdings Ltd., a Singapore-based hospital and healthcare company, partnered with Substipharm Biologics to enhance vaccine access. This partnership aims to improve the availability of the IMOJEV Japanese encephalitis vaccine across nine Asian markets, utilizing Zuellig Pharma's marketing, distribution, and ZP Therapeutics' expertise. Substipharm Biologics, a France-based pharmaceutical company, develops various vaccines, including those for encephalitis and encephalomyelitis.

Major players in the encephalomyelitis market are Merck & Co. Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., HiFiBiO Therapeutics, Zoetis Services LLC, Chugai Pharmaceutical Co. Ltd., IDEXX, Abcam Limited., EUROIMMUN Medizinische Labordiagnostika AG, Eurogentec S.A., Boehringer Ingelheim International GmbH, Creative Diagnostics, Atlas Antibodies, AnaSpec, VMRD Inc., Antibodies Incorporated, Fresenius Kabi, Hemispherx Biopharma Inc., BioStoneah, YouSeq Ltd.

North America was the largest region in the encephalomyelitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in encephalomyelitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the encephalomyelitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The encephalomyelitis market consists of revenues earned by entities by providing services such as chest X-rays and CT scans, rapid diagnostic tests, sputum cultures, and blood cultures. The market value includes the value of related goods sold by the service provider or included within the service offering. The encephalomyelitis market also includes sales of antiviral therapy, and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Encephalomyelitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on encephalomyelitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for encephalomyelitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The encephalomyelitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Equine Encephalomyelitis; Associated Encephalomyelitis; Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG); Encephalomyelitis Disseminata; Acute Disseminated Encephalomyelitis; AIDS-Related Encephalomyelitis; Other Types
• 2) By Treatment: Surgery ; Plasmapheresis; Drug Treatment; Other Treatments
• 3) By End-users: Clinics ; Hospitals; Other End-Users
• Subsegments:
• 1) By Equine Encephalomyelitis: Eastern Equine Encephalomyelitis; Western Equine Encephalomyelitis; Venezuelan Equine Encephalomyelitis
• 2) By Associated Encephalomyelitis: Acute Disseminated Encephalomyelitis; Paraneoplastic Encephalomyelitis; Infectious Encephalomyelitis
• 3) By Anti-Myelin Oligodendrocyte Glycoprotein Antibody: Monophasic Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis; Relapsing Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis
• 4) By Encephalomyelitis: Viral Encephalomyelitis; Bacterial Encephalomyelitis; Autoimmune Encephalomyelitis
• Companies Mentioned: Merck & Co. Inc.; Sanofi S.A.; F. Hoffmann-La Roche Ltd.; HiFiBiO Therapeutics; Zoetis Services LLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Encephalomyelitis Market Characteristics

3. Encephalomyelitis Market Trends And Strategies

4. Encephalomyelitis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Encephalomyelitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Encephalomyelitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Encephalomyelitis Market Growth Rate Analysis
• 5.4. Global Encephalomyelitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Encephalomyelitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Encephalomyelitis Total Addressable Market (TAM)

6. Encephalomyelitis Market Segmentation

• 6.1. Global Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Equine Encephalomyelitis
• Associated Encephalomyelitis
• Anti-Myelin Oligodendrocyte Glycoprotein Antibody (AntiMOG)
• Encephalomyelitis Disseminata
• Acute Disseminated Encephalomyelitis
• AIDS-Related Encephalomyelitis
• Other Types
• 6.2. Global Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Surgery
• Plasmapheresis
• Drug Treatment
• Other Treatments
• 6.3. Global Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clinics
• Hospitals
• Other End-Users
• 6.4. Global Encephalomyelitis Market, Sub-Segmentation Of Equine Encephalomyelitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eastern Equine Encephalomyelitis
• Western Equine Encephalomyelitis
• Venezuelan Equine Encephalomyelitis
• 6.5. Global Encephalomyelitis Market, Sub-Segmentation Of Associated Encephalomyelitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute Disseminated Encephalomyelitis
• Paraneoplastic Encephalomyelitis
• Infectious Encephalomyelitis
• 6.6. Global Encephalomyelitis Market, Sub-Segmentation Of Anti-Myelin Oligodendrocyte Glycoprotein Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monophasic Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis
• Relapsing Myelin Oligodendrocyte Glycoprotein Antibody Encephalomyelitis
• 6.7. Global Encephalomyelitis Market, Sub-Segmentation Of Encephalomyelitis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Viral Encephalomyelitis
• Bacterial Encephalomyelitis
• Autoimmune Encephalomyelitis

7. Encephalomyelitis Market Regional And Country Analysis

• 7.1. Global Encephalomyelitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Encephalomyelitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Encephalomyelitis Market

• 8.1. Asia-Pacific Encephalomyelitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Encephalomyelitis Market

• 9.1. China Encephalomyelitis Market Overview
• 9.2. China Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Encephalomyelitis Market

• 10.1. India Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Encephalomyelitis Market

• 11.1. Japan Encephalomyelitis Market Overview
• 11.2. Japan Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Encephalomyelitis Market

• 12.1. Australia Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Encephalomyelitis Market

• 13.1. Indonesia Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Encephalomyelitis Market

• 14.1. South Korea Encephalomyelitis Market Overview
• 14.2. South Korea Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Encephalomyelitis Market

• 15.1. Western Europe Encephalomyelitis Market Overview
• 15.2. Western Europe Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Encephalomyelitis Market

• 16.1. UK Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Encephalomyelitis Market

• 17.1. Germany Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Encephalomyelitis Market

• 18.1. France Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Encephalomyelitis Market

• 19.1. Italy Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Encephalomyelitis Market

• 20.1. Spain Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Encephalomyelitis Market

• 21.1. Eastern Europe Encephalomyelitis Market Overview
• 21.2. Eastern Europe Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Encephalomyelitis Market

• 22.1. Russia Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Encephalomyelitis Market

• 23.1. North America Encephalomyelitis Market Overview
• 23.2. North America Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Encephalomyelitis Market

• 24.1. USA Encephalomyelitis Market Overview
• 24.2. USA Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Encephalomyelitis Market

• 25.1. Canada Encephalomyelitis Market Overview
• 25.2. Canada Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Encephalomyelitis Market

• 26.1. South America Encephalomyelitis Market Overview
• 26.2. South America Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Encephalomyelitis Market

• 27.1. Brazil Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Encephalomyelitis Market

• 28.1. Middle East Encephalomyelitis Market Overview
• 28.2. Middle East Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Encephalomyelitis Market

• 29.1. Africa Encephalomyelitis Market Overview
• 29.2. Africa Encephalomyelitis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Encephalomyelitis Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Encephalomyelitis Market, Segmentation By End-users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Encephalomyelitis Market Competitive Landscape And Company Profiles

• 30.1. Encephalomyelitis Market Competitive Landscape
• 30.2. Encephalomyelitis Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. HiFiBiO Therapeutics Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Zoetis Services LLC Overview, Products and Services, Strategy and Financial Analysis

31. Encephalomyelitis Market Other Major And Innovative Companies

• 31.1. Chugai Pharmaceutical Co. Ltd.
• 31.2. IDEXX
• 31.3. Abcam Limited.
• 31.4. EUROIMMUN Medizinische Labordiagnostika AG
• 31.5. Eurogentec S.A.
• 31.6. Boehringer Ingelheim International GmbH
• 31.7. Creative Diagnostics
• 31.8. Atlas Antibodies
• 31.9. AnaSpec
• 31.10. VMRD Inc.
• 31.11. Antibodies Incorporated
• 31.12. Fresenius Kabi
• 31.13. Hemispherx Biopharma Inc.
• 31.14. BioStoneah
• 31.15. YouSeq Ltd.

32. Global Encephalomyelitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Encephalomyelitis Market

34. Recent Developments In The Encephalomyelitis Market

35. Encephalomyelitis Market High Potential Countries, Segments and Strategies

• 35.1 Encephalomyelitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Encephalomyelitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Encephalomyelitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료